Emergent BioSolutions (EBS) Net Income towards Common Stockholders Growth (1y) (2012 - 2026)
Emergent BioSolutions (EBS) Net Income towards Common Stockholders Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn | 71.83% |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn | -0.17% |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn | -14.68% |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn | -90.23% |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn | 2,405.06% |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn | -14.93% |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn | - |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn | 62.34% |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn | -286.15% |
| 10 | Emergent BioSolutions | 427.92 Mn | 266.42 Mn | 84.10 Mn | -90.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -90.00% |
| Dec 31, 2025 | -74.44% |
| Sep 30, 2025 | -55.40% |
| Jun 30, 2025 | 95.76% |
| Mar 31, 2025 | 655.56% |
| Dec 31, 2024 | 36.77% |
| Sep 30, 2024 | 143.58% |
| Jun 30, 2024 | -8.30% |
| Mar 31, 2024 | 104.83% |
| Dec 31, 2023 | 26.12% |
| Sep 30, 2023 | -202.41% |
| Jun 30, 2023 | -363.48% |
| Mar 31, 2023 | -4,932.43% |
| Dec 31, 2022 | -137.66% |
| Sep 30, 2022 | -166.36% |
| Jun 30, 2022 | -1,326.09% |
| Mar 31, 2022 | -105.31% |
| Dec 31, 2021 | -4.41% |
| Sep 30, 2021 | -182.78% |
| Jun 30, 2021 | -95.04% |